RGEN - Repligen Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
68.86
+1.83 (+2.73%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close67.03
Open67.54
Bid67.00 x 1000
Ask68.73 x 800
Day's Range67.54 - 70.41
52 Week Range42.80 - 71.21
Volume462,532
Avg. Volume368,511
Market Cap3.252B
Beta (3Y Monthly)1.01
PE Ratio (TTM)149.70
EPS (TTM)0.46
Earnings DateJul 31, 2019 - Aug 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est72.29
  • IBD Stock Of The Day Nearly Triples Its Rivals' Performance This Year
    Investor's Business Daily3 days ago

    IBD Stock Of The Day Nearly Triples Its Rivals' Performance This Year

    Repligen stock is the IBD Stock Of The Day after the medical technology company "shot the lights out" during the first quarter, and posted its best organic revenue growth in three years.

  • Why Is No One Talking About Repligen Stock?
    Motley Fool3 days ago

    Why Is No One Talking About Repligen Stock?

    The business enables the safe and cost-efficient production of biopharmaceuticals -- and that's been a remarkably lucrative niche.

  • Zacks.com featured highlights include: Strategic Education, Repligen, Kinsale Capital, Arcosa and OSI Systems
    Zacks3 days ago

    Zacks.com featured highlights include: Strategic Education, Repligen, Kinsale Capital, Arcosa and OSI Systems

    Zacks.com featured highlights include: Strategic Education, Repligen, Kinsale Capital, Arcosa and OSI Systems

  • 3 Reasons Why Growth Investors Shouldn't Overlook Repligen (RGEN)
    Zacks4 days ago

    3 Reasons Why Growth Investors Shouldn't Overlook Repligen (RGEN)

    Repligen (RGEN) could produce exceptional returns because of its solid growth attributes.

  • Mallinckrodt Ends Enrollment in Phase III for Terlipressin
    Zacks12 days ago

    Mallinckrodt Ends Enrollment in Phase III for Terlipressin

    Mallinckrodt (MNK) concludes enrollment in the phase III study on terlipressin, currently under development for treating adult patients with Hepatorenal Syndrome Type 1.

  • Thomson Reuters StreetEvents17 days ago

    Edited Transcript of RGEN earnings conference call or presentation 9-May-19 12:30pm GMT

    Q1 2019 Repligen Corp Earnings Call

  • Repligen (RGEN) Q1 2019 Earnings Call Transcript
    Motley Fool17 days ago

    Repligen (RGEN) Q1 2019 Earnings Call Transcript

    RGEN earnings call for the period ending March 31, 2019.

  • Repligen (RGEN) Q1 Earnings and Revenues Beat Estimates
    Zacks18 days ago

    Repligen (RGEN) Q1 Earnings and Revenues Beat Estimates

    Repligen (RGEN) delivered earnings and revenue surprises of 7.69% and 0.21%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press18 days ago

    Repligen: 1Q Earnings Snapshot

    The Waltham, Massachusetts-based company said it had net income of 17 cents per share. Earnings, adjusted for one-time gains and costs, came to 28 cents per share. The drug developer posted revenue of ...

  • GlobeNewswire18 days ago

    Repligen Reports First Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance

    Reports first quarter revenue of $60.6 million, representing 35% year-over-year growth and 37% organic growthRaises revenue guidance to $235-$241 million for full year 2019,.

  • ACCESSWIRE18 days ago

    Repligen Corp. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 9, 2019 / Repligen Corp. (NASDAQ: RGEN ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 9, 2019 at 8:30 AM Eastern Time. ...

  • Is Repligen's (NASDAQ:RGEN) Share Price Gain Of 273% Well Earned?
    Simply Wall St.19 days ago

    Is Repligen's (NASDAQ:RGEN) Share Price Gain Of 273% Well Earned?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and...

  • Evoke Pharma (EVOK) to Post Q1 Earnings: What's in Store?
    Zacks19 days ago

    Evoke Pharma (EVOK) to Post Q1 Earnings: What's in Store?

    During Evoke Pharma's (EVOK) Q1 conference call, investor focus will be on its progress and issues related to the NDA submission for Gimoti to treat diabetic gastroparesis.

  • Markit20 days ago

    See what the IHS Markit Score report has to say about Repligen Corp.

    Repligen Corp NASDAQ/NGS:RGENView full report here! Summary * Bearish sentiment is moderate and increasing * Economic output in this company's sector is expanding Bearish sentimentShort interest | NegativeShort interest is moderately high for RGEN with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on April 29. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $3.67 billion over the last one-month into ETFs that hold RGEN are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Turtle Beach (HEAR) to Report Q1 Earnings: What's in Store?
    Zacks21 days ago

    Turtle Beach (HEAR) to Report Q1 Earnings: What's in Store?

    Solid product performance and excellent market position, driven by innovation, quality products, strong brand and retail partnerships, are likely to drive Turtle Beach's (HEAR) first-quarter results.

  • GlobeNewswire25 days ago

    Repligen to Report First Quarter 2019 Financial Results

    WALTHAM, Mass., May 02, 2019 -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2019 financial results on Thursday, May 9,.

  • GlobeNewswire27 days ago

    Repligen Corporation Prices Public Offering of Shares of Common Stock

    Repligen Corporation (RGEN) today announced the pricing of an underwritten public offering of 2,734,375 shares of its common stock at a public offering price of $64.00 per share. In addition, Repligen Corporation has granted the underwriters a 30-day option to purchase up to an additional 410,156 shares of its common stock at the public offering price, less underwriting discounts and commissions. Repligen expects proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, to be approximately $175 million, excluding any exercise of the underwriters’ option to purchase additional shares.

  • GlobeNewswire28 days ago

    Repligen Corporation Announces Proposed Public Offering of Shares of Common Stock

    Repligen Corporation (RGEN) today announced that it has commenced an underwritten public offering of $175,000,000 in shares of its common stock. In addition, Repligen Corporation expects to grant the underwriters a 30-day option to purchase up to an additional $26,250,000 in shares of its common stock in connection with the proposed public offering. All shares of common stock will be offered by Repligen Corporation.

  • Here’s What Hedge Funds Think About Repligen Corporation (RGEN)
    Insider Monkey28 days ago

    Here’s What Hedge Funds Think About Repligen Corporation (RGEN)

    Does Repligen Corporation (NASDAQ:RGEN) represent a good buying opportunity at the moment? Let’s briefly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and throw away millions of dollars on satellite photos and other research activities, so it is no wonder why they tend to […]

  • Why Sony, Repligen, and Capital One Financial Jumped Today
    Motley Foollast month

    Why Sony, Repligen, and Capital One Financial Jumped Today

    Favorable earnings helped to send many stocks higher.

  • GlobeNewswirelast month

    Repligen Corporation Announces Agreement to Acquire Process Analytics Innovator C Technologies and Reports Preliminary First Quarter 2019 Financial Results

    Repligen Corporation (RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive agreement to acquire privately-held C Technologies, Inc. for approximately $240 million, comprised of $192 million in cash plus $48 million in Repligen common stock.

  • Repligen CEO got 356 percent pay bump for 2018
    American City Business Journalslast month

    Repligen CEO got 356 percent pay bump for 2018

    Repligen raised CEO Tony Hunt's pay from $3,044,785 in 2017 to $13,893,326 last year — an increase of 356 percent.

  • Before You Buy Repligen Corporation (NASDAQ:RGEN), Consider Its Volatility
    Simply Wall St.2 months ago

    Before You Buy Repligen Corporation (NASDAQ:RGEN), Consider Its Volatility

    If you own shares in Repligen Corporation (NASDAQ:RGEN) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of volatility. Volatility is considered to be a m...